---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-23-030175"
form_type: "8-K"
ticker: "OCGN"
cik: "0001372299"
company_name: "Ocugen, Inc."
filed_at: "2023-08-22T23:59:59+00:00"
generated_at: "2026-06-11T05:30:25.406633+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.4
calibrated_materiality_score: 0.4
confidence: "low"
source: SEC EDGAR
---

# Ocugen reports Q2 2023 financial results; pipeline update highlights NR2E3 gene therapy

## Summary
- Reported financial results for quarter ended June 30, 2023; no specific figures available in filing text.
- Business update discussed gene therapy programs including NR2E3 modifier gene and NHR platform.
- Presentation materials furnished as Exhibit 99.1 describe 'molecular reset' approach for retinal diseases.

## SEC filing metadata
- accession: 0001628280-23-030175
- form_type: 8-K
- ticker: OCGN
- cik: 0001372299
- company_name: Ocugen, Inc.
- filed_at: 2023-08-22T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.4
- calibrated_materiality_score: 0.4
- confidence: low
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/0001628280-23-030175-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/ocgn-20230822.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-23-030175
- JSON: https://secwatch.observer/filing/0001628280-23-030175.json
- Plain text: https://secwatch.observer/filing/0001628280-23-030175.txt

## Key facts
- Earnings Releases
  Ocugen, Inc. reported financial results for the quarter ended June 30, 2023.
  - Period: the quarter ended June 30, 2023
  - Result: reported results
  source text: Ocugen, Inc. (the "Company") held a conference call and webcast earlier today to discuss its financial results for the quarter ended June 30, 2023, along with a general business update.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1372299/000162828023030175/0001628280-23-030175-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.